Alteration in innate immune cues assessed by analyzing peripheral blood immune system in post-covid patients
- Authors: Dobrynina M.A.1,2, Zurochka A.V.1,3, Komelkova M.V.1,3, Zurochka V.A.1,3, Praskurnichiy E.A.2, Ryabova L.V.4, Sarapultsev A.P.1,3
-
Affiliations:
- Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences
- State Research Center of the Russian Federation — Federal Medical Biophysical Center named after A.I. Burnazyan of the Federal Medical and Biological Agency of the Russian Federation
- South Ural State University (National Research University)
- South Ural State Medical University of the Ministry of Health of the Russian Federation
- Issue: Vol 13, No 5 (2023)
- Pages: 864-872
- Section: ORIGINAL ARTICLES
- URL: https://journals.rcsi.science/2220-7619/article/view/158889
- DOI: https://doi.org/10.15789/2220-7619-AII-9641
- ID: 158889
Cite item
Full Text
Abstract
The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has led to global morbidity and mortality. Some patients fully recover from COVID-19, whereas around 45% subjects suffer from various persistent symptoms (fatigue, cognitive impairment, impaired thermoregulation, skin diseases, etc.) for at least four months after SARS-CoV-2 infection regardless of disease severity. Such persistent post-infection effects are known as long-COVID, post-acute effects of COVID-19, or post-COVID state. SARS-CoV-2 infection is accompanied by damage to the innate immune system. Considering the role of natural killer cells and the activation of the complement system in COVID-19 as well as the regulatory properties related to CD46 and its potential involvement in cell virus entry, we found necessary to study immune system parameters associated with impairment of these innate immune cues on various leukocyte subpopulations in post-COVID patients. We studied 92 immune system parameters, including: pan-leukocyte markers for gated lymphocytes, phenotyping of T cells, T-helper inducers, cytotoxic T-lymphocytes, NK- and TNK-cells, T-regulatory cells/suppressors, B-lymphocytes, including B-memory cells, activated helpers, early activation of lymphocytes, activated T-lymphocytes, and late lymphocyte activation markers. Levels of total IgM, IgG, IgA, specific IgM, IgG to coronavirus COVID-19, C1-inhibitor, C3a, and C5a complement components were measured by enzyme immunoassay using Multiscan FC Thermoscientific enzyme immunoassay analyzer (China) and Vector Best reagent kits (Russia). A complete blood count was conducted to study 25 parameters: leukocyte, erythrocyte, and platelet hematopoietic lineages as well as the quantitative and qualitative composition of hematopoietic lineages. Our study results showed that in some patients, six months after suffering from COVID-19, there was a decrease in the level of NK cells (48%) and CD46+ pan-leukocyte marker cells (64.5%). A decrease in NK cell levels was accompanied by increased level of total T- and B-lymphocytes, and altered platelet and erythroid hematopoietic lineages. In patients with reduced CD46 expression on T-lymphocytes, both their total count and NK cell count were significantly reduced. Our data also suggest that CD46 might be potentially involved in development of SARS-CoV-2 infection and the post-COVID state. Thus, in 50–65% of patients who have experienced SARS-CoV-2 infection, damage to the innate immune system persists after six months being accompanied by impaired erythroid and platelet hematopoietic lineages. The data obtained indicate a need for using immunocorrective therapy in such patients.
Full Text
##article.viewOnOriginalSite##About the authors
Maria A. Dobrynina
Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences; State Research Center of the Russian Federation — Federal Medical Biophysical Center named after A.I. Burnazyan of the Federal Medical and Biological Agency of the Russian Federation
Author for correspondence.
Email: mzurochka@mail.ru
PhD (Medicine), Researcher, Laboratory of Immunology of the Inflammation; Associate Professor, Department of Internal Medicine, Medical and Biological University of Innovation and Continuing Education
Russian Federation, Yekaterinburg; MoscowAleksandr V. Zurochka
Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences; South Ural State University (National Research University)
Email: av_zurochka@mail.ru
DSc (Medicine), Professor, Honored Scientist of the Russian Federation, Leading Researcher; Head of the Biotechnology Laboratory, Russian-Chinese Center
Russian Federation, Yekaterinburg; ChelyabinskMariia V. Komelkova
Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences; South Ural State University (National Research University)
Email: mkomelkova@mail.ru
DSc (Biology), Head of the Laboratory of Systemic Pathology and Promising Medicines, Russian-Chinese Center
Russian Federation, Yekaterinburg; ChelyabinskVladimir A. Zurochka
Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences; South Ural State University (National Research University)
Email: v_zurochka@mail.ru
DSc (Medicine), Senior Researcher; Senior Researcher, Biotechnology Laboratory, Russian-Chinese Center
Russian Federation, Yekaterinburg; ChelyabinskEvgeny A. Praskurnichiy
State Research Center of the Russian Federation — Federal Medical Biophysical Center named after A.I. Burnazyan of the Federal Medical and Biological Agency of the Russian Federation
Email: praskurnichey@mail.ru
DSc (Medicine), Professor, Head of the Department of Internal Medicine, Medical and Biological University of Innovation and Continuing Education
Russian Federation, MoscowLiana V. Ryabova
South Ural State Medical University of the Ministry of Health of the Russian Federation
Email: lianarabowa@rambler.ru
DSc (Medicine), Associate Professor, Professor of the Department of Life Safety, Disaster Medicine, Emergency Medicine
Russian Federation, ChelyabinskAlexey P. Sarapultsev
Institute of Immunology and Physiology, Ural Branch of the Russian Academy of Sciences; South Ural State University (National Research University)
Email: a.sarapultsev@gmail.com
DSc (Biology), Leading Researcher, Laboratory of Immunopathophysiology; Head of the Russian-Chinese Center
Russian Federation, Yekaterinburg; ChelyabinskReferences
- Зурочка А.В., Хайдуков С.В., Кудрявцев И.В., Черешнев В.А. Проточная цитометрия в биомедицинских исследованиях. Екатеринбург: РИО УрО РАН, 2018. 720 с. [Zurochka A.V., Khaidukov S.V., Kudryavtsev I.V., Chereshnev V.A. Flow cytometry in biomedical research. Ekaterinburg: RIO Ural Branch of the Russian Academy of Sciences, 2018. 720 p. (In Russ.)]
- Хайдуков С.В., Байдун Л.А., Зурочка А.В., Тотолян А.А. Стандартизованная технология «Исследование субпопуляционного состава лимфоцитов периферической крови с применением проточных цитофлюориметров-анализаторов» // Российский иммунологический журнал. 2014. Т. 8, № 4 (17). С. 974–992. [Khaydukov S.V., Baidun L.A., Zurochka A.V., Totolian A.A. Standardized technology «Study of the subpopulation composition of peripheral blood lymphocytes using flow cytofluorometer-analyzers». Rossiiskii immunologicheskii zhurnal = Russian Journal of Immunology, 2014, vol. 8, no. 4 (17), pp. 974–992. (In Russ.)]
- Agergaard J., Ullahammer W.M., Gunst J.D., Østergaard L., Schiøttz-Christensen B. Characteristics of a Danish post-COVID cohort referred for examination due to persistent symptoms six months after mild acute COVID-19. J. Clin. Med., 2022, vol. 11, no. 24: 7338. doi: 10.3390/jcm11247338
- Ashraf U.M., Abokor A.A., Edwards J.M., Waigi E.W., Royfman R.S., Hasan S.A., Smedlund K.B., Hardy A.M.G., Chakravarti R., Koch L.G. SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol. Genomics., 2021, vol. 53. no. 2, pp. 51–60. doi: 10.1152/physiolgenomics.00087.2020
- Cheong J.G., Ravishankar A., Sharma S., Parkhurst C.N., Grassmann S.A., Wingert C.K., Laurent P., Ma S., Paddock L., Miranda I.C., Karakaslar E.O., Nehar-Belaid D., Thibodeau A., Bale M.J., Kartha V.K., Yee J.K., Mays M.Y., Jiang C., Daman A.W., Martinez de Paz A., Ahimovic D., Ramos V., Lercher A., Nielsen E., Alvarez-Mulett S., Zheng L., Earl A., Yallowitz A., Robbins L., LaFond E., Weidman K.L., Racine-Brzostek S., Yang H.S., Price D.R., Leyre L., Rendeiro A.F., Ravichandran H., Kim J., Borczuk A.C., Rice C.M., Jones R.B., Schenck E.J., Kaner R.J., Chadburn A., Zhao Z., Pascual V., Elemento O., Schwartz R.E., Buenrostro J.D., Niec R.E., Barrat F.J., Lief L., Sun J.C., Ucar D., Josefowicz S.Z. Epigenetic memory of coronavirus infection in innate immune cells and their progenitors. Cell, 2023, vol. 186, no. 18, pp. 3882–3902.e24. doi: 10.1016/j.cell.2023.07.019
- Costa L.B., Perez L.G., Palmeira V.A., Macedo E., Cordeiro T., Ribeiro V.T., Lanza K., Simões E., Silva A.C. Insights on SARS-CoV-2 molecular interactions with the renin-angiotensin system. Front. Cell Dev. Biol., 2020, vol. 8: 559841. doi: 10.3389/fcell.2020.559841
- D’Alessandro M., Bergantini L., Cameli P., Curatola G., Remediani L., Sestini P., Bargagli E.; Siena COVID Unit. Peripheral biomarkers’ panel for severe COVID-19 patients. J. Med. Virol., 2021, vol. 93, no. 3, pp. 1230–1232. doi: 10.1002/jmv.26577
- Hawkins E.D., Oliaro J. CD46 signaling in T cells: linking pathogens with polarity. FEBS Lett., 2010, vol. 584, no. 24, pp. 4838–4844. doi: 10.1016/j.febslet.2010.09.003
- Iba T., Levy J.H. Thrombosis and thrombocytopenia in COVID-19 and after COVID-19 vaccination. Trends Cardiovasc. Med., 2022, vol. 32, no. 5, pp. 249–256. doi: 10.1016/j.tcm.2022.02.008
- Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J., 2021, vol. 40, no. 16: e107821. doi: 10.15252/embj.2021107821
- Le Friec G., Sheppard D., Whiteman P., Karsten C.M., Shamoun S.A., Laing A., Bugeon L., Dallman M.J., Melchionna T., Chillakuri C., Smith R.A., Drouet C., Couzi L., Fremeaux-Bacchi V., Köhl J., Waddington S.N., McDonnell J.M., Baker A., Handford P.A., Lea S.M., Kemper C. The CD46-Jagged1 interaction is critical for human TH1 immunity. Nat. Immunol., 2012, vol. 13, no. 12, pp. 1213–1221. doi: 10.1038/ni.2454
- Leowattana W., Leowattana T., Leowattana P. Circulating angiotensin converting enzyme 2 and COVID-19. World J. Clin. Cases, 2022, vol. 10, no. 34, pp. 12470–12483. doi: 10.12998/wjcc.v10.i34.12470
- Li M., Guo W., Dong Y., Wang X., Dai D., Liu X., Wu Y., Li M., Zhang W., Zhou H., Zhang Z., Lin L., Kang Z., Yu T., Tian C., Qin R., Gui Y., Jiang F., Fan H., Heissmeyer V., Sarapultsev A., Wang L., Luo S., Hu D. Elevated exhaustion levels of NK and CD8+ T cells as indicators for progression and prognosis of COVID-19 disease. Front. Immunol., 2020, vol. 11: 580237. doi: 10.3389/fimmu.2020.580237
- Liszewski M.K., Atkinson J.P. Membrane cofactor protein (MCP; CD46): deficiency states and pathogen connections. Curr. Opin. Immunol., 2021, vol. 72, pp. 126–134. doi: 10.1016/j.coi.2021.04.005
- Liu W., Li H. COVID-19: attacks the 1-beta chain of hemoglobin to disrupt respiratory function and escape immunity by capsid-like system. ChemRxiv. Cambridge: Cambridge Open Engage, 2023. doi: 10.26434/chemrxiv-2021-dtpv3-v12
- Masselli E., Vaccarezza M., Carubbi C., Pozzi G., Presta V., Mirandola P., Vitale M. NK cells: a double edge sword against SARS-CoV-2. Adv. Biol. Regul., 2020, vol. 77: 100737. doi: 10.1016/j.jbior.2020.100737
- Mitsuyama Y., Yamakawa K., Kayano K., Maruyama M., Wada T., Fujimi S. Prolonged enhancement of cytotoxic T lymphocytes in the post-recovery state of severe COVID-19. J. Intensive Care, 2021, vol. 9, no. 1: 76. doi: 10.1186/s40560-021-00591-3
- Munblit D., Nicholson T., Akrami A., Apfelbacher C., Chen J., De Groote W., Diaz J.V., Gorst S.L., Harman N., Kokorina A., Olliaro P., Parr C., Preller J., Schiess N., Schmitt J., Seylanova N., Simpson F., Tong A., Needham D.M., Williamson P.R., PC-COS project steering committee. A core outcome set for post-COVID-19 condition in adults for use in clinical practice and research: an international Delphi consensus study. Lancet Respir. Med., 2022, vol. 10, no. 7, pp. 715–724. doi: 10.1016/S2213-2600(22)00169-2
- Ni Choileain S., Astier A.L. CD46 processing: a means of expression. Immunobiology, 2012, vol. 217, no. 2, pp. 169–175. doi: 10.1016/ j.imbio.2011.06.003
- Oliaro J., Pasam A., Waterhouse N.J., Browne K.A., Ludford-Menting M.J., Trapani J.A., Russell S.M. Ligation of the cell surface receptor, CD46, alters T cell polarity and response to antigen presentation. Proc. Natl Acad. Sci. USA, 2006, vol. 103, no. 49, pp. 18685–18690. doi: 10.1073/pnas.0602458103
- O’Mahoney L.L., Routen A., Gillies C., Ekezie W., Welford A., Zhang A., Karamchandani U., Simms-Williams N., Cassambai S., Ardavani A., Wilkinson T.J., Hawthorne G., Curtis F., Kingsnorth A.P., Almaqhawi A., Ward T., Ayoubkhani D., Banerjee A., Calvert M., Shafran R., Stephenson T., Sterne J., Ward H., Evans R.A., Zaccardi F., Wright S., Khunti K. The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis. EClinicalMedicine, 2022, vol. 55: 101762. doi: 10.1016/j.eclinm.2022.101762
- Pasini E., Corsetti G., Romano C., Scarabelli T.M., Chen-Scarabelli C., Saravolatz L., Dioguardi F.S. Serum metabolic profile in patients with long-Covid (PASC) syndrome: clinical implications. Front. Med. (Lausanne), 2021, vol. 8: 714426. doi: 10.3389/fmed.2021.714426
- Persson B.D., John L., Rafie K., Strebl M., Frängsmyr L., Ballmann M.Z., Mindler K., Havenga M., Lemckert A., Stehle T., Carlson L.A., Arnberg N. Human species D adenovirus hexon capsid protein mediates cell entry through a direct interaction with CD46. Proc. Natl Acad. Sci. USA, 2021, vol. 118, no. 3: e2020732118. doi: 10.1073/pnas.2020732118
- Rendeiro A.F., Casano J., Vorkas C.K., Singh H., Morales A., DeSimone R.A., Ellsworth G.B., Soave R., Kapadia S.N., Saito K., Brown C.D., Hsu J., Kyriakides C., Chiu S., Cappelli L.V., Cacciapuoti M.T., Tam W., Galluzzi L., Simonson P.D., Elemento O., Salvatore M., Inghirami G. Profiling of immune dysfunction in COVID-19 patients allows early prediction of disease progression. Life Sci. Alliance, 2020, vol. 4, no. 2: e202000955. doi: 10.26508/lsa.202000955
- Ruenjaiman V., Sodsai P., Kueanjinda P., Bunrasmee W., Klinchanhom S., Reantragoon R., Tunvirachaisakul C., Manothummetha K., Mejun N., Liengswangwong K., Torvorapanit P., Paitoonpong L., Putcharoen O., Palaga T., Hirankarn N.; study team. Impact of SARS-CoV-2 infection on the profiles and responses of innate immune cells after recovery. J. Microbiol. Immunol. Infect., 2022, vol. 55, no. 6, pt. 1, pp. 993–1004. doi: 10.1016/j.jmii.2022.09.001
- Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V., WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis., 2022, vol. 22, no. 4, pp. e102–e107. doi: 10.1016/S1473-3099(21)00703-9
- Steenblock C., Toepfner N., Beuschlein F., Perakakis N., Mohan Anjana R., Mohan V., Mahapatra N.R., Bornstein S.R. SARS-CoV-2 infection and its effects on the endocrine system. Best Pract. Res. Clin. Endocrinol. Metab., 2023: 101761. doi: 10.1016/j.beem.2023.101761
- Stein K.R., Gardner T.J., Hernandez R.E., Kraus T.A., Duty J.A., Ubarretxena-Belandia I., Moran T.M., Tortorella D. CD46 facilitates entry and dissemination of human cytomegalovirus. Nat. Commun., 2019, vol. 10, no. 1:2699. doi: 10.1038/s41467-019-10587-1
- Sumbalova Z., Kucharska J., Palacka P., Rausova Z., Langsjoen P.H., Langsjoen A.M., Gvozdjakova A. Platelet mitochondrial function and endogenous coenzyme Q10 levels are reduced in patients after COVID-19. BratislLekListy, 2022, vol. 123, no. 1, pp. 9–15. doi: 10.4149/BLL_2022_002
- Verdecchia P., Cavallini C., Spanevello A., Angeli F. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. Eur. J. Intern. Med., 2020, vol. 76, pp. 14–20. doi: 10.1016/j.ejim.2020.04.037
- Wang C., Yu C., Jing H., Wu X., Novakovic V.A., Xie R., Shi J. Long COVID: the nature of thrombotic sequelae determines the necessity of early anticoagulation. Front. Cell Infect. Microbiol., 2022, vol. 12: 861703. doi: 10.3389/fcimb.2022.861703
- Wenzhong L., Hualan L. COVID-19: attacks the 1-beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. ChemRxiv. Cambridge: Cambridge Open Engage, 2020. doi: 10.26434/chemrxiv.11938173.v9.
- Wu Y., Huang X., Sun J., Xie T., Lei Y., Muhammad J., Li X., Zeng X., Zhou F., Qin H., Shao L., Zhang Q. Clinical characteristics and immune injury mechanisms in 71 patients with COVID-19. mSphere, 2020, vol. 5, no. 4: e00362-20. doi: 10.1128/mSphere.00362-20